The following article is part of conference coverage from the 2018 American College of Rheumatology and Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, Illinois. Rheumatology Advisor’s staff will be reporting breaking news associated with research conducted by leading experts in rheumatology. Check back for the latest news from ACR/ARHP 2018 .

CHICAGO – There is no significant difference in risk for atrial fibrillation (AF) or cardiovascular disease (CVD) following initiation of ustekinumab or a tumor necrosis factor inhibitor (TNFi) in patients with psoriasis (PsO) or psoriatic arthritis (PsA), according to the results of a large cohort study presented at the ACR/ARHP 2018 Annual Meeting, October 19-24, in Chicago, Illinois.

The investigators sought to explore the comparative CV risk with different biologic disease-modifying antirheumatic drugs in patients with PsO or PsA. They used 2 large US commercial databases — Optum Clinformatics and MarketScan — to identify patients with a diagnosis of either PsO or PsA who had initiated treatment with ustekinumab or a TNFi (ie, adalimumab, etanercept, infliximab, certolizumab, or golimumab) between September 25, 2009, and September 30, 2015.


Continue Reading

The primary study outcome was incident AF. The secondary outcome comprised a composite CV event that included myocardial infarction, stroke, and coronary revascularization. All participants were followed until the first occurrence of 1 of the following events: study outcomes; death; plan disenrollment; switching agents; or discontinuing therapy.

A total of 60,028 adult patients with PsO or PsA and no prior AF were identified — 15,470 from Optum and 44,558 from MarketScan. Mean participant age was 47.2 ± 12.7 years; 51% of the patients were women. Among the participants, 81% had a diagnosis of PsO and 46% had PsA; 27% of the patients had both PsO and PsA.

Related Articles

Overall, 60 cases of incident AF were reported among 9071 people taking ustekinumab compared with 323 AF incident cases among 50,957 people taking a TNFi (incidence rate [IR], 4.7 and 5.0 cases per 1000 person-years, respectively). Major adverse cardiac events (MACE) occurred in 74 people taking ustekinumab vs 421 people taking a TNFi (IR, 6.2 and 6.1 cases per 1000 person-years, respectively). The combined hazard ratio for AF in those taking ustekinumab compared those taking a TNFi was 1.15 (95% CI, 0.70-1.89). For MACE, the hazard ratio was 1.14 (95% CI, 0.89-1.46).

The investigators concluded that although no substantial difference in risk for AF or CVD was reported following initiation of ustekinumab or TNFi therapy, a possible small effect cannot be ruled out. Additional studies with a longer follow-up period are thus warranted.

For more coverage of ACR/ARHP 2018, click here.

Reference   

Lee M, Desai RJ, Jin Y, Brill G, Ogdie A, Kim SC. Comparative risk of atrial fibrillation and cardiovascular events between TNF-inhibitors and ustekinumab in patients with psoriasis and psoriatic arthritis: a population-based multi-database study. Presented at: 2018 American College of Rheumatology/ Association of Rheumatology Health Professionals Annual Meeting; October 19-24, 2018; Chicago, IL. Abstract 1615.

This information is brought to you by Haymarket Media and is not sponsored by, nor a part of, the American College of Rheumatology.